The invention provides an aqueous ophthalmic composition, containing a beta blocker such as timolol, carteolol or the like, and a sugar alcohol such as mannitol, sorbitol or the like, optionally together with boric acid. The composition of the invention can improve the corneal permeability of a drug, so that the dose of the drug can be lowered, for example by decreasing the frequency of application to the eyes. It is therefore expected that the risk of systemic side effects which may be induced ...

The invention provides an aqueous ophthalmic composition, containing a beta blocker such as timolol, carteolol or the like, and a sugar alcohol such as mannitol, sorbitol or the like, optionally together with boric acid. The composition of the invention can improve the corneal permeability of a drug, so that the dose of the drug can be lowered, for example by decreasing the frequency of application to the eyes. It is therefore expected that the risk of systemic side effects which may be induced ...

The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers,such as Carteolol, Levobunolol, Betaxolol,...

The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers, such as Carteolol, Levobunolol, Betaxolol...

An aqueous composition for ophthalmic administration which contains a ss-blocker typified by, for example, timolol or carteolol and a sugar alcohol typified by mannitol or sorbitol optionally together with boric acid. The aforesaid composition can increase the corneal permeability of a drug. As a result, the drug dosage can be decreased, e.g., a lowering in the frequency of ophthalmic administration. Thus, it is expected that the risk of systemic side effects such as cardio toxicity or respirato...

Composicion farmacéutica de administracion oral que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos betabloqueantes para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 2: Composicion farmacéutica segun la reivindicacion 1 donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 4: Composicion farmacéutica segun la reivindicacion 1 donde el radical alqui...